Correction to: Scientific Reports https://doi.org/10.1038/s41598-023-49948-8, published online 02 January 2024
The Competing interests section in the original version of this Article was incorrect.
“The authors declare no competing interests.”
now reads:
“The authors listed below report the following details of affiliation or involvement in an organization or entity with a financial interest in the subject matter or materials discussed in this manuscript.
LM, GP, GF, CMQ, GF, MB, GM are employed in Aboca who produce and commercialize the product indicated in the manuscript as B. VM is Honorary President of Aboca SPA. CS is the scientific responsible of a project related to the topic of the present manuscript and committed by Aboca to C.E.M.I.N (UniPG). Product A is a generic drug containing Omeprazole, while “Product B”, Neobianacid, is a Medical device made of substances. Both products are indicated for the treatment reflux diseases and functional dyspepsia.”
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mattoli, L., Proietti, G., Fodaroni, G. et al. Publisher Correction: Suspect screening analysis to improve untargeted and targeted UHPLC-qToF approaches: the biodegradability of a proton pump inhibitor medicine and a natural medical device. Sci Rep 14, 5660 (2024). https://doi.org/10.1038/s41598-024-53924-1
Published:
DOI: https://doi.org/10.1038/s41598-024-53924-1
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
